当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.

Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.

Abstract：

:The paramyxoviruses respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) are the two most common agents of severe lower respiratory tract disease in infants and children throughout the world. RSV causes yearly epidemics of bronchiolitis and pneumonia in infants and young children, while PIV3 is a common cause of bronchiolitis, pneumonia and croup. Together these two agents account for up to 30% of all hospitalizations of infants and young children for respiratory tract disease. A licensed vaccine is not currently available for either of these viruses. Development of vaccines against diseases caused by RSV and PIV3 is one of the priorities of the Global Programme for Vaccines (GPV). On 27 March 1994, GPV sponsored a workshop in Nyon, Switzerland, to review the status of vaccine development for these pathogens and to explore new methods of immunization that might be applied to the prevention of diseases caused by RSV and PIV. Furthermore, the World Health Organization (WHO) wished to assess progress in the development of methodologies to rescue infectious virus from cDNA clones of RSV and PIV3. This technology, when developed, will be extremely valuable in developing new vaccine candidates and in unravelling the genetic basis of attenuation of existing vaccines. This paper summarizes the findings presented at this one-day meeting.

journal_name

Vaccine

journal_title

Vaccine

authors

Crowe JE Jr

doi

10.1016/0264-410x(95)98266-d

subject

Has Abstract

pub_date

1995-03-01 00:00:00

pages

415-21

issue

4

eissn

0264-410X

issn

1873-2518

pii

0264-410X(95)98266-D

journal_volume

13

pub_type

相关文献

VACCINE文献大全
  • Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations.

    abstract：:This article presents the World Health Organization's (WHO) recommendations for the use of vaccines against diseases caused by human papillomaviruses (HPV) from the WHO position paper on Human papillomavirus vaccines: WHO position paper - October 2014, recently published in the Weekly Epidemiological Record [1]. This ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.12.002

    authors：

    更新日期：2015-08-26 00:00:00

  • Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity.

    abstract：OBJECTIVE:This study sought to evaluate the acceptability of inactivated influenza vaccine delivered by microneedle patch (MNP) in comparison to inactivated influenza vaccine (IIV) delivered by hypodermic needle. DESIGN, SETTING, AND PARTICIPANTS:From the general population of Atlanta, Georgia, we screened 112 and enr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.07.064

    authors： Frew PM,Paine MB,Rouphael N,Schamel J,Chung Y,Mulligan MJ,Prausnitz MR

    更新日期：2020-10-21 00:00:00

  • Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study.

    abstract：INTRODUCTION:We estimated influenza vaccine effectiveness (IVE) to prevent laboratory-confirmed influenza-related hospitalizations in patients 18 years old or older during the 2010-2011 influenza season. METHODS:We conducted a prospective case-control study in five hospitals, in Valencia, Spain. Study subjects were co...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.vaccine.2012.07.006

    authors： Puig-Barberà J,Díez-Domingo J,Arnedo-Pena A,Ruiz-García M,Pérez-Vilar S,Micó-Esparza JL,Belenguer-Varea A,Carratalá-Munuera C,Gil-Guillén V,Schwarz-Chavarri H

    更新日期：2012-08-24 00:00:00

  • Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG.

    abstract：:Groups of calves (20 per group) were vaccinated subcutaneously with a single dose of BCG Pasteur (6 x 10(4) or 6 x 10(6) colony forming units) and two months later, 15 calves from each group were challenged intratracheally with virulent Mycobacterium bovis. Vaccination with either dose of BCG induced significant prote...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(94)00055-r

    authors： Buddle BM,de Lisle GW,Pfeffer A,Aldwell FE

    更新日期：1995-08-01 00:00:00

  • Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine.

    abstract：:In anticipation of future combination vaccines, a recombinant class 3 porin (rPorB) of group B meningococci was evaluated as an alternative carrier protein for a Haemophilus influenzae type b (Hib) polyribosylribotol phosphate (PRP) conjugate vaccine. The use of rPorB may avoid undesirable immunologic interactions amo...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00174-1

    authors： Fusco PC,Michon F,Laude-Sharp M,Minetti CA,Huang CH,Heron I,Blake MS

    更新日期：1998-11-01 00:00:00

  • Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia, Spain.

    abstract：:The prevalence of seropositive individuals that makes costs of vaccinating all individuals equal to that for screening and vaccination of susceptible individuals is defined as the critical prevalence of antibodies (p*). Screening and vaccination is more efficient when the prevalence of seropositive individuals (p) in ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.03.048

    authors： Plans-Rubió P

    更新日期：2004-09-28 00:00:00

  • Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season.

    abstract：BACKGROUND:The 2015/2016 influenza season was characterized in Europe by the circulation of A(H1N1)pdm09 clade 6B.1 and B/Victoria-lineage influenza viruses. The components of the vaccines used in the current and past two seasons in the Valencia region were similar but not well matched to the 2015/2016 dominant influen...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.10.100

    authors： Puig-Barberà J,Guglieri-López B,Tortajada-Girbés M,López-Labrador FX,Carballido-Fernández M,Mollar-Maseres J,Schwarz-Chavarri G,Baselga-Moreno V,Mira-Iglesias A,Díez-Domingo J,Valencia Hospital Network for the Study of Influenza, Res

    更新日期：2017-12-19 00:00:00

  • Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.

    abstract：:Plague is a zoonotic disease caused by Yersinia pestis, an etiological agent of pneumonic and bubonic plague. There is a need for an improved plague vaccine that may overcome the limitation of presently available whole cell vaccine. An alternative approach described here, is the use of protective epitopes from immunod...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.01.031

    authors： Tripathi V,Chitralekha KT,Bakshi AR,Tomar D,Deshmukh RA,Baig MA,Rao DN

    更新日期：2006-04-12 00:00:00

  • Delivering the promise of the Decade of Vaccines: opportunities and challenges in the development of high quality new vaccines.

    abstract：:The Decade of Vaccines (DoV) initiative, launched in 2010, has as its mission "to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live". Through their life-saving vaccines, the research-based vaccine companies represented by th...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2012.12.032

    authors： Keith JA,Agostini Bigger L,Arthur PA,Maes E,Daems R

    更新日期：2013-04-18 00:00:00

  • Colinear synthesis of an antigen-specific B-cell epitope with a 'promiscuous' tetanus toxin T-cell epitope: a synthetic peptide immunocontraceptive.

    abstract：:Carrier conjugation is commonly used to provide T-cell help for small, linear peptides containing antigen-specific B-cell epitopes. However, carrier conjugation is expensive, variable and often results in adverse side effects if the conjugate is administered repeatedly. To eliminate the need for carrier conjugation, w...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(97)00105-9

    authors： O'Hern PA,Liang ZG,Bambra CS,Goldberg E

    更新日期：1997-11-01 00:00:00

  • Case-control vaccine effectiveness studies: Data collection, analysis and reporting results.

    abstract：:The case-control methodology is frequently used to evaluate vaccine effectiveness post-licensure. The results of such studies provide important insight into the level of protection afforded by vaccines in a 'real world' context, and are commonly used to guide vaccine policy decisions. However, the potential for bias a...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2017.04.035

    authors： Verani JR,Baqui AH,Broome CV,Cherian T,Cohen C,Farrar JL,Feikin DR,Groome MJ,Hajjeh RA,Johnson HL,Madhi SA,Mulholland K,O'Brien KL,Parashar UD,Patel MM,Rodrigues LC,Santosham M,Scott JA,Smith PG,Sommerfelt H,Tate

    更新日期：2017-06-05 00:00:00

  • Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.

    abstract：:In a phase III, double blind, randomized, noninferiority, multi-centre clinical trial, 817 infants were included and randomly assigned to vaccination with DTaP-IPV(Vero) (N=410) or DTaP-IPV(Mkc) (N=407) vaccines (Statens Serum Institut (SSI), Denmark) in the right thigh. All infants were vaccinated with Act-HIB (Sanof...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.vaccine.2008.07.033

    authors： Pietrzyk JJ,Wysocki J,Pejcz J,Galaj A,Majda-Stanislawska E,Käyhty H,Thierry-Carstensen B,Jensen AM

    更新日期：2008-09-26 00:00:00

  • Low mortality after mild measles infection compared to uninfected children in rural West Africa.

    abstract：BACKGROUND:It has been assumed that measles infection may be associated with persistent immune suppression and long-term excess mortality. However, few community studies of mortality after measles infection have been carried out. We examined long-term mortality for measles cases, sub-clinical measles cases, and uninfec...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00430-9

    authors： Aaby P,Simondon F,Samb B,Cisse B,Jensen H,Lisse IM,Soumaré M,Whittle H

    更新日期：2002-11-22 00:00:00

  • Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen.

    abstract：:Reconstituted influenza virus (A/PR/8 strain) envelopes (RIVE) and influenza virus (A/Sichuan/87 (H3N2) strain) surface antigens were entrapped in dehydration-rehydration vesicles (DRV liposomes) composed of egg phosphatidylcholine (PC) or distearoyl phosphatidylcholine (DSPC DRV) and equimolar (32 mumol) cholesterol....

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(92)90509-i

    authors： Gregoriadis G,Tan L,Ben-Ahmeida ET,Jennings R

    更新日期：1992-01-01 00:00:00

  • Recombinant protein vaccines produced in insect cells.

    abstract：:The baculovirus-insect cell expression system is a well known tool for the production of complex proteins. The technology is also used for commercial manufacture of various veterinary and human vaccines. This review paper provides an overview of how this technology can be applied to produce a multitude of vaccine cand...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2012.01.016

    authors： Cox MM

    更新日期：2012-02-27 00:00:00

  • In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses.

    abstract：:Carcinoembryonic antigen (CEA), which is expressed in several cancer types, is a potential target for specific immunotherapy. In this study, the feasibility of using dendrite cells (DCs) for tumor immunotherapy after transduction with a recombinant adenovirus containing CEA gene (AdVCEA) was investigated. The recombin...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(03)00569-3

    authors： Cho HI,Kim HJ,Oh ST,Kim TG

    更新日期：2003-12-12 00:00:00

  • Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo.

    abstract：:A DNA vaccine codifying the mycobacterial hsp65 can prevent infection with Mycobacterium tuberculosis in a prophylactic setting and also therapeutically reduce the number of bacteria in infected mice. The protective mechanism is thought to be related to Th1-mediated events that result in bacterial killing. To determin...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(03)00543-7

    authors： Lima KM,dos Santos SA,Santos RR,Brandão IT,Rodrigues JM Jr,Silva CL

    更新日期：2003-12-08 00:00:00

  • Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.

    abstract：:Antibodies to the epitope EFRH, representing residues 3-6 within the beta-amyloid (Abeta) sequence, were previously shown to affect the solubility and disaggregation of Abeta fibrils in vitro. Here, we describe a novel method of immunization, using as antigen the EFRH peptide displayed on the surface of the filamentou...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00609-6

    authors： Frenkel D,Dewachter I,Van Leuven F,Solomon B

    更新日期：2003-03-07 00:00:00

  • Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles.

    abstract：:Recombinant hepatitis B surface antigen (HBsAg) particles derived from Chinese hamster ovary (CHO) cells were stored at various conditions for 12-18 months in their naked form or adsorbed to alum (HBV vaccine). The physical, chemical and immunological parameters during storage at -20 degrees C, 4 degrees C, room tempe...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(99)00149-8

    authors： Diminsky D,Moav N,Gorecki M,Barenholz Y

    更新日期：1999-08-20 00:00:00

  • Immunopathological responses and kinetics of Brucella melitensis Rev 1 infection after subcutaneous or conjunctival vaccination in rams.

    abstract：:The innocuousness of the Brucella melitensis Rev 1 live attenuated vaccine strain has never been fully assessed in rams. The immunopathological responses and the kinetics and distribution of the infection induced by this strain were determined after subcutaneous or conjunctival vaccination in both young (3-4 months ol...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.03.030

    authors： Muñoz PM,de Miguel MJ,Grilló MJ,Marín CM,Barberán M,Blasco JM

    更新日期：2008-05-19 00:00:00

  • Surveillance for adverse events after DTwP/Hib vaccination in Brazil: sensitivity and factors associated with reporting.

    abstract：:We estimated the sensitivity, i.e., the proportion of all cases of adverse events following immunization (AEFIs) reported to the Brazilian passive surveillance for adverse events following immunization (PSAEFI) with the diphtheria-tetanus-whole-cell pertussis-Haemophilus influenzae type b (DTwP/Hib) vaccine, as well a...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.02.059

    authors： Monteiro SA,Takano OA,Waldman EA

    更新日期：2010-04-19 00:00:00

  • Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.

    abstract：:Cholera is a potentially lethal diarrhea disease caused by the gram-negative bacterium Vibrio cholerae. The need for an effective cholera vaccine is clearly indicated but the challenges of eliciting both systemic and mucosal immune responses remains a significant challenge. In the current report, we discovered that a ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.04.008

    authors： Xu G,Wang S,Zhuang L,Hackett A,Gu L,Zhang L,Zhang C,Wang H,Huang Z,Lu S

    更新日期：2009-06-12 00:00:00

  • Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice.

    abstract：:Japanese encephalitis (JE) is the most important cause of acute encephalitis syndrome (AES). Japanese encephalitis virus (JEV), the prototype member of the JE serocomplex, belongs to the genus Flavivirus. The immunogenic proteins envelope (E) and non-structural protein 1 (NS1) of JEV are widely explored for the develo...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.11.088

    authors： Nath B,Vandna,Saini HM,Prasad M,Kumar S

    更新日期：2020-02-11 00:00:00

  • The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007).

    abstract：:All hospital discharges and deaths related to CAP and pneumococcal-pneumonia from adults over 50 from 2003 to 2007 in Spain were obtained. Among the 447,670 Pneumonia-all causes discharges 17% were pneumococcal pneumonia. The annual hospitalisation rate was 6.27 and 1.09 cases per 1000, respectively. 75,932 deaths for...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.11.025

    authors： Gil-Prieto R,García-García L,Alvaro-Meca A,Méndez C,García A,de Miguel AG

    更新日期：2011-01-10 00:00:00

  • Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.

    abstract：:We previously observed that a detoxified Escherichia coli O111, Rc chemotype J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) vaccine protected animals from experimental lethal sepsis when immune antibodies were given passively as treatment at the onset of fever or when vaccine was giv...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0264-410x(03)00483-3

    authors： Cross AS,Opal SM,Palardy JE,Drabick JJ,Warren HS,Huber C,Cook P,Bhattacharjee AK

    更新日期：2003-11-07 00:00:00

  • Evaluation of a Salmonella Enteritidis vaccine and related ELISA for respective induction and assessment of acquired immunity to the vaccine and/or Echinacea purpurea in Awassi Ewes.

    abstract：:The aim of this study was to evaluate an experimental Salmonella Enteritidis (SE) bacterin and an indirect ELISA system to assess quantitatively the acquired immunity in Awassi ewes to the vaccine and/or Echinacea purpurea (EP) dried roots. Four treatments of the ewes were included in the experimental design, with 6 e...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.03.035

    authors： Barbour EK,Assi CAA,Shaib H,Hamadeh S,Murtada M,Mahmoud G,Yaghmoor S,Iyer A,Harakeh S,Kumosani T

    更新日期：2015-05-05 00:00:00

  • Human schistosomiasis: potential consequences of vaccination.

    abstract：:The potential outcomes of a Phase II schistosomiasis vaccine trial are explored using mathematical models which assume some natural immunity and a vaccine providing partial protection for a limited time. Analyses suggest that vaccination may have only a limited impact on life-long cumulative worm burdens and may lead ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(95)00083-d

    authors： Woolhouse ME

    更新日期：1995-08-01 00:00:00

  • Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situ

    abstract：:Patients with malignancies are considered to be at increased risk of acquiring influenza. Because of higher complication and case fatality rates, preventive measures such as vaccination are of great interest. The objective of this study was to assess the acceptability, tolerability and immunogenicity of an adjuvant-fr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.09.005

    authors： Lagler H,Tobudic S,Ramharter M,Elandt K,Sperr WR,Redlberger-Fritz M,Popow-Kraupp T,Jäger U,Zielinski CC,Burgmann H

    更新日期：2012-11-06 00:00:00

  • Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use.

    abstract：:Glycoconjugate vaccines have been proven safe and effective against various diseases in children. Although these vaccines have a history of effectiveness, there are still many unanswered questions to be addressed, including conjugate interference when multiple vaccines are administered at one time, expansion of seroty...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2010.04.072

    authors： Shinefield HR

    更新日期：2010-06-17 00:00:00

  • Transcutaneous vaccination with virus-like particles.

    abstract：:Virus-like particles (VLP) are inert, empty capsids of viruses, which contain no DNA/RNA from the virus itself. However they retain the structure of a virus and they can be engineered to have antigens attached. We have constructed VLP, derived from Rabbit hemorrhagic disease virus, and shown they are highly immunogeni...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.03.052

    authors： Young SL,Wilson M,Wilson S,Beagley KW,Ward V,Baird MA

    更新日期：2006-06-29 00:00:00